Identifying acute myeloid leukemia subtypes based on pathway enrichment

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a prevalent cancer with limited survival improvements despite targeted therapies.
• Personalized treatment approaches are crucial for improving outcomes in AML, especially for older patients.

Purpose of the Study:

• To develop a novel subtyping method for acute myeloid leukemia (AML) to understand its molecular heterogeneity.
• To identify distinct AML subtypes based on pathway enrichment for guiding personalized treatment strategies.

Main Methods:

• Unsupervised clustering was performed using enrichment scores from 14 pathways (metabolism, immunity, DNA repair, oncogenic signaling).
• Four independent AML datasets were analyzed to ensure consistency of identified subtypes.
• Subtypes were characterized by gene expression, stemness, proliferation, homeostasis, migration, mutation status, and chemotherapy sensitivity.

Main Results:

• Three consistent AML subtypes were identified: DNA repair (DR), immune-enriched (ImE), and immune-deprived (ImD).
• DR subtypes show high DNA repair/metabolic activity, stemness, proliferation, and chemotherapy sensitivity.
• ImD subtypes have favorable prognosis, low immune/oncogenic pathway activity, and low mutation rates.
• ImE subtypes exhibit high immune/oncogenic pathway activity, low stemness, high migration, and low chemotherapy sensitivity.

Conclusions:

• A novel pathway enrichment-based subtyping approach effectively categorizes AML molecular heterogeneity.
• The identified DR, ImD, and ImE subtypes provide a promising framework for developing personalized AML treatment strategies.
• This subtyping method can guide therapeutic decisions by predicting patient response and prognosis.